We analyzed the BRAFV600E mutation because it is the most frequently detected mutation in melanoma, it has been studied extensively in pre-clinical models as a driver of the malignant phenotype(reviewed in [20]), and understanding its role in melanomagenesis is highly relevant to current clinical trials with BRAF and MAPK pathway inhibitors. This evidence concerns the gene BRAF and melanoma.